Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis

MDGRPHaCS / shutterstock.com

The ACR Releases an Updated Treatment Guideline for Rheumatoid Arthritis

Ruth Jessen Hickman, MD  |  June 14, 2021

In early June, the ACR released an updated guideline on the management of rheumatoid arthritis, which includes new recommendations for specific high-risk groups.1 The guideline includes 44 recommendations—seven of which are strong and 37 conditional. It underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Guideline Development Process At…

Studies Probe Treating Rheumatoid Arthritis with Vagus Nerve Stimulation

Jason Liebowitz, MD, FACR  |  June 14, 2021

When rheumatologists think about rheumatoid arthritis (RA), they are apt to picture the synovium, contemplate such antibodies as rheumatoid factor and those to citrullinated proteins, and consider how this interplay of factors manifests in disease. What is not as commonly discussed is the role the autonomic nervous system plays in the pathogenesis and symptomatology of…

RA Shortens Life Expectancy of Patients with RA & Increases Healthcare Costs

Arthritis & Rheumatology  |  April 27, 2021

RA shortens life expectancy, even with advances in treatment—and more so for women than for men, according to new research by Chiu et al.

Non-Invasive Vagus Nerve Stimulation Tolerated, Effective for Rheumatoid Arthritis

Lisa Rapaport  |  March 24, 2021

(Reuters Health)—Non-invasive vagus nerve stimulation is safe and effective as an intervention for rheumatoid arthritis (RA), a small proof-of-concept study suggests. The study enrolled 35 patients with active RA and an inadequate response to therapy with disease-modifying anti-rheumatic drugs (DMARDs). All DMARDS were discontinued four weeks prior to the trial. For the study, all participants…

Highlights, Pearls & News from ACR Convergence 2020

Vanessa Caceres  |  March 15, 2021

ACR CONVERGENCE 2020—In a year like no other, the 2020 virtual ACR Convergence was a meeting like no other. Nonetheless, the meeting introduced a healthy mix of clinical insights and take-home pearls, according to panelists in the meeting’s closing session, Bright Future: Discovery & Growth.  In this session, panelists discussed some of the biggest news…

Micromotors Promising for Rheumatoid Arthritis Therapy

Marilynn Larkin  |  March 10, 2021

NEW YORK (Reuters Health)—Magnesium-based micromotors showed promise as a delivery system for hydrogen therapy to inflamed joints in an experimental model of rheumatoid arthritis, researchers say. Hydrogen gas has been shown to neutralize overproduction of reactive oxygen species (ROS), which can degrade cartilage and bone and activate inflammatory cytokines, according to Dr. Yingfeng Tu of…

Study Explores Palindromic Rheumatism to Predict RA Development

Ruth Jessen Hickman, MD  |  March 4, 2021

Research from Ellingwood et al. examines how often patients diagnosed with early RA experience episodic joint inflammation and describes characteristics that may result in RA development.

Modern Treatment Tied to Low Disease Activity in Pregnant RA Patients

Lisa Rapaport  |  February 24, 2021

(Reuters Health)—Many pregnant women with rheumatoid arthritis (RA) may achieve low disease activity in the third trimester with a modern treatment regimen that includes anti-tumor necrosis factor (TNF) medications, a recent study suggests. Researchers examined data on 309 patients with RA who were pregnant or trying to conceive and who were treated with modern treat-to-target…

A High HAQ at Baseline in Early RA Is a Bad Sign

Arthritis & Rheumatology  |  January 26, 2021

In this study, Fatima et al. analyzed how well the Health Assessment Questionnaire (HAQ) disability index predicts future all-cause mortality in patients with early RA (i.e., with a symptom duration of less than one year). A total of 1,724 patients with early RA were included. The researchers found that a higher HAQ score and Disease Activity Score at one year were significantly associated with all-cause mortality.

Researchers Propose a Sensitive, Specific Biomarker for Rheumatoid Arthritis

Deborah Levenson  |  January 19, 2021

A proposed biomarker may improve the diagnosis of rheuma­toid arthritis (RA). Writing in Arthritis & Rheumatology, researchers at Pleasanton, Calif.-based Roche Sequencing Solutions and the University of Toronto say their biomarker, constructed by profiling a comprehensive set of antibodies via high-density peptide array, has high specificity and sensitivity for RA, compared with commercially available assays.1…

  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 74
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences